Drug intelligence / Profile preview

HD vehicle-GNP

Development stage: Unknown
Lead developer: Gylden Pharma
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intradermal

Overview

HD vehicle-GNP is a high-dose vehicle control used in clinical trials for Gylden Pharma's dengue vaccine candidate, PepGNP-Dengue. It consists of gold nanoparticles (GNP) without the synthetic peptides that constitute the active vaccine. In the naNO-DENGUE Phase I trial (NCT04935801), it served as a comparator to evaluate the safety and background effects of the nanoparticle platform. The platform, developed by Gylden Pharma under the leadership of Professor Thomas Rademacher, is designed to induce CD8+ T cell immunity against all four dengue virus serotypes while minimizing the risk of antibody-dependent enhancement (ADE).

Other names: vehicle-GNPgold nanoparticles without peptides

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on HD vehicle-GNP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD vehicle-GNP.

Explore the full profile